TCRX vs MLCI Comparison

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.